Digestive system

HempFusion Closes Acquisition of Apothecanna

Retrieved on: 
Tuesday, August 3, 2021
MEN, General Health, Other Retail, Tobacco, Consumer, Convenience store, Retail, Public relations, Investor relations, Women, Communications, Alternative medicine, Health, Bacteriology, Digestive system, Probiotic

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (HempFusion or the Company), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce that it has completed its previously announced acquisition of APCNA Holdings LLC (Apothecanna) (the Transaction).

Key Points: 
  • HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (HempFusion or the Company), a leading health and wellness Company offering premium probiotic supplements and products containing CBD, is pleased to announce that it has completed its previously announced acquisition of APCNA Holdings LLC (Apothecanna) (the Transaction).
  • With the recent Sagely Naturals acquisition and now closing of the Apothecanna acquisition, HempFusion is in its strongest position to date.
  • The Transaction was completed pursuant to the terms of the unit purchase agreement dated May 14, 2021, as amended (the Purchase Agreement) among HempFusion, Apothecanna, all holders of Apothecanna interests (the Sellers) and Jeff Henretig, as representative of the Sellers.
  • HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations.

OMNi-BiOTiC® Stress Release Awarded Probiotic of the Year by NutraIngredients USA

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Magazines, Digestive system, Bacteriology, Sympathetic nervous system, Biotic, Probiotic, Klaus Kleinfeld, Omni, Stress

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Omni-Biotic Stress Release is named "Product of the Year" in the probiotic category at the NutraIngredients USA Awards 2021.

Key Points: 
  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Omni-Biotic Stress Release is named "Product of the Year" in the probiotic category at the NutraIngredients USA Awards 2021.
  • CEO of Allergosan USA, Klaus Kleinfeld, adds: "It's an honor to have Omni-Biotic Stress Release recognized as the Probiotic of the Year.
  • Studied in controlled clinical trials, the supplementation of Omni-Biotic Stress Release showed improved mood , memory, cognition, stress response , and gastro-intestinal comfort .
  • The company is dedicated to delivering targeted probiotic blends for specific indications including stress, immunity, liver detox and more.

Avalife Is Supporting the Brain Through the Stomach

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Anatomy, Digestive system, Environmental microbiology, Firmicutes, Microbiomes, Organs anatomy), Brain, Gut–brain axis, Mental health

In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.

Key Points: 
  • In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.
  • A growing body of research has revealed how closely the brain and the gut work together a phenomenon known as the "gut-brain axis."
  • About Avalife: Avalife's parent company, Avacare Global, was founded by Dr. Vikram Naik in South Africa in 1997.
  • Avacare is the company's division that is focused on holistic solutions and targets natural and complementary medicine in pursuit of that end.

Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue

Retrieved on: 
Thursday, July 29, 2021
Medical specialties, Branches of biology, Medicinal plants, Medicine, Bacteriology, Digestive system, Entheogens, Euphoriants, Prebiotic, Cannabis, Bifidobacterium, Medical cannabis

OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Key Points: 
  • OTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc("Tetra" or the Company")(TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that itfiled a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.
  • GRAS status will allow for the broad application of this novel ingredient in foods as well as dietary supplements.
  • Research conducted through Tetra has shown that cannabis plant residue can increase the growth of beneficial gut microbes including bothLactobaccillus rhamnosusandBifidobacterium longum.
  • If granted, this patent application will provide Tetra with protection for the use of cannabis plant residue material containing residual cannabinoids within a specified profile range, as an oral prebiotic component alone or in combination with other pro, post, para, or prebiotics as a dietary supplement for gastrointestinal health.

Making progress in developing probiotic beverages without animal protein

Retrieved on: 
Wednesday, July 28, 2021
Food and drink, Branches of biology, Dairy products, Digestive system, Non-alcoholic drinks, Dietary Supplements, Nutrition, Milk, Protein, Casein, Probiotic, Rice protein

Most products enriched with probiotics and protein are made with dairy products.

Key Points: 
  • Most products enriched with probiotics and protein are made with dairy products.
  • The nutritional value of these proteins must therefore be improved to be comparable to that of animal proteins.
  • The team led by Professor Monique Lacroix has demonstrated that fermenting drinks fortified with pea and rice proteins yields the same quality of protein as casein, an animal protein found in milk.
  • This allows the production of peptides (protein fragments)resulting from the breakdown of proteins during fermentation, thereby facilitating their absorption during digestion.

Smidge Small Batch Supplements® Brand Launches, Offers Customers Premium Products In Minimalistic Form And A Holistic Approach To Health

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Bacteriology, Digestive system, Nutrition, Biotic, Vitamin, Probiotic, Health

SOUTHFIELD, Mich., July 26, 2021 /PRNewswire/ -- When it comes to health, minutia matters. That's the belief behind Smidge Small Batch Supplements® – formerly called Organic 3 – which recently launched a line of premium supplements that includes probiotics, digestive enzymes, whole food vitamins and natural minerals. The brand also introduced a more streamlined online shopping experience at GetSmidge.com.

Key Points: 
  • That's the belief behind Smidge Small Batch Supplements formerly called Organic 3 which recently launched a line of premium supplements that includes probiotics, digestive enzymes, whole food vitamins and natural minerals.
  • "At Smidge, we believe that food is medicine, you are what you digest and good nutrition is the root of wellness.
  • Everyone at Smidgehas a genuine, heartfelt concern for the well-being of our customers and their journey back to health.
  • Smidge Small Batch Supplementsthoroughly vets all raw materials, and all product ingredients are tested for potency, purity and nutritional value in third-party labs.

Probiotics Market by Application, Ingredient, Form, End User and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 23, 2021
General Health, Health, Fitness & Nutrition, Medical specialties, Bacteriology, Digestive system, Probiotics, Branches of biology, Clinical medicine, Dietary supplement, Biotic

The "Global Probiotics Market by Application (Functional Food & Beverages (Dairy Products, Non-dairy Beverages, Infant Formula, Cereals), Dietary Supplements, Feed), Ingredient (Bacteria, Yeast), Form (Dry, Liquid), End User, & Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Probiotics Market by Application (Functional Food & Beverages (Dairy Products, Non-dairy Beverages, Infant Formula, Cereals), Dietary Supplements, Feed), Ingredient (Bacteria, Yeast), Form (Dry, Liquid), End User, & Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global probiotics market is estimated to be valued at USD 61.1 billion in 2021 and is projected to reach USD 91.1 billion by 2026, at a CAGR of 8.3% during the forecast period.
  • Factors affecting the growth of the probiotics market are health benefits associated with probiotic-fortified foods and technological advancements in probiotic products.
  • Based on application, the food & beverages segment is estimated to account for the largest share in the probiotics market in 2020.

Virtual Lecture on First-of-its-Kind Research Exploring the Influence of Pet Ownership on the Gut Microbiome

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Microbiomes, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Digestive system, Gut microbiota, Microbiota, Human microbiome, Cardiovascular disease, Microbiome

WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.

Key Points: 
  • WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.
  • This lecture, titled "The association of pet ownership, the gut microbiome, and cardiovascular disease risk among older adults", features Dr. Katharine Watson, MA, BVMS, discussing her active HABRI-funded study, "The influence of pet ownership on gut microbiota composition and cardiovascular disease risk among 50 to 85-year old United States adults".
  • The human microbiota is made up of trillions of cells, with the biggest populations residing in the gut.
  • Much of the science on the physical health benefits of pets involve the association between pet ownership and physical activity.

Health-Ade Launches Pop, Prebiotic Soda Line with Low Sugar and Real Gut Health Benefits, Rounding Out Gut Healthy Beverage Portfolio

Retrieved on: 
Wednesday, July 21, 2021
Drinks, Branches of biology, Medical specialties, Soft drinks, Convenience foods, Bacteriology, Digestive system, Carbonated drinks, Kombucha, Prebiotic, Drink mixer

Health-Ade Pop comes at a time when there's a groundswell of interest in gut health and its connection to overall health.

Key Points: 
  • Health-Ade Pop comes at a time when there's a groundswell of interest in gut health and its connection to overall health.
  • In addition, 77% of consumers intend to make more attempts to stay healthy in the future (2021 WGSN Trend Curve Gut Health Report).
  • Given these important trends, the shelf-stable soda rounds out Health-Ade's offerings, giving consumers an on-the-go beverage that supports gut health with a low sugar, all-natural prebiotic formulation that meets the growing consumer demand for a healthy soda with functional benefits.
  • The brand's growing roster of offerings now includes Health-Ade Pop, a low sugar prebiotic soda, Health-Ade Plus, an adaptogenic kombucha line, and Health-Ade Mixers, designed for a low sugar, mixologist quality cocktail solution at home.

New Study of a Novel Metabolic Procedure with Self-Assembling Magnets for Obese Patients with Type 2 Diabetes deemed Safe and Feasible

Retrieved on: 
Tuesday, July 20, 2021
Medical specialties, Clinical medicine, Medicine, Anastomosis, Angiology, Digestive system, Evolutionary biology, Surgery

The aim of the study was to determine the technical feasibility and safety of sutureless duodeno-ileal side-side anastomosis in obese patients with type 2 diabetes using self-assembling magnets.

Key Points: 
  • The aim of the study was to determine the technical feasibility and safety of sutureless duodeno-ileal side-side anastomosis in obese patients with type 2 diabetes using self-assembling magnets.
  • A dual-path enteral diversion with large-caliber and durable anastomosis was achieved in all patients enrolled in the study.
  • "This publication validates the safety and feasibility for self-assembling magnets and the potential to reshape the landscape in metabolic surgery."
  • In 2020 the FDA granted Breakthrough Therapy designation on GI Window's self-assembling magnets, for a small bowel application.